Ikshana Therapeutics, Inc. is developing groundbreaking treatments for age-related diseases, with a focus on restoring vision for those suffering from dry age-related macular degeneration (AMD). The innovative approach targets the mechanistic target of rapamycin complex1 (mTORC1) signaling pathway, a key regulator of autophagy - the process of cellular renewal and rejuvenation. By modulating mTORC1 activity, Ikshana aims to reactivate autophagy and unlock the body's own restorative mechanisms, paving the way for transformative therapies that could dramatically improve the quality of life for millions. This cutting-edge science holds immense potential to address unmet needs and deliver life-changing outcomes for the aging population.